<DOC>
	<DOCNO>NCT02011984</DOCNO>
	<brief_summary>Non-randomized multicenter post-market study confirm long-term safety effectiveness CE-approved Camouflage-coated self-expandable RESISTANT Camouflage stent system revascularization de novo stenotic lesion superficial femoral artery 100 compliant patient suitable stent angioplasty . The CE-approved device use accord intend use . Beyond standard care intervention schedule . Therefore , trial subject exception rule §23b German Medical Device Act ( MPG ) , include national implementation EC directive 93/42/EEC .</brief_summary>
	<brief_title>Multicentric Non-randomized Investigation RESISTANT Camouflage Stent-system</brief_title>
	<detailed_description>The aim non-randomized post-market clinical follow-up study confirm long-term safety effectiveness CE-approved Camouflage-coated self expandable RESISTANT Camouflage stent system revascularization de novo stenotic lesion superficial femoral artery 120 compliant patient suitable stent angioplasty . The primary end point target lesion revascularization 12 month . Further follow-up schedule discharge , 30 day , 6 24 month .</detailed_description>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>Age 18 95 year Male nonpregnant female De novo lesion &gt; 70 % occlusion SFA ( Superficial Femoral Artery ) arteries suitable stent angioplasty Max . 1 lesion within leg treat study lesion Lesions length range ≥3 cm ≤18 cm A patent inflow artery free significant lesion ( &gt; 50 % stenosis ) confirm angiography . Treatment target lesion acceptable successful treatment inflow artery lesion . Reference vessel diameter ≥3 mm ≤ 7 mm Successful guide wire passage lesion Symptomatic peripheral artery disease ( Rutherford stage 2 5 ) Patient willing provide inform consent comply require followup visit , test schedule , medication regimen Patients antiplatelet therapy , anticoagulant thrombolytic contraindicate Patients present lasting intraluminal thrombosis lesion thrombolytic therapy Perforation location angioplasty characterize secretion contrast medium Aneurysm artery treat All common contraindication PTA ( Percutaneous Transluminal Angioplasty ) Contraindications stent angioplasty Hypersensitivity/allergy nickeltitanium Hypersensitivity/allergy component delivery &amp; dilation system Severe renal insufficiency ( creatinine &gt; 2.0 mg/dL glomerular filtration rate &lt; 60 ml/min/1.73 ) Uncorrected bleed disorder Major gastrointestinal bleeding within last 6 month . Ipsilateral intervention target vessel Untreated ipsilateral iliac artery stenosis &gt; 70 % Previous stenting prior surgery SFA Instent restenosis Acute myocardial infarct within 72 h Less one patent crural artery Popliteal stenosis &gt; 70 % Manifest hyperthyroidism Acute onset symptom Legthreatening ischemia Multimorbid patient poor general condition Pregnant woman become pregnant &lt; 2 yr Living 100 km apart study center Patient actively participate another investigational device drug study History hemorrhagic stroke within 3 month Previous plan surgical interventional procedure within 30 day procedure Acute subacute thrombus target vessel Acute vessel occlusion sudden symptom onset Lesions target area require atherectomy ( ablative device ) , cut balloon , cryoplasty balloon , advanced device facilitate angioplasty balloon stent delivery Use adjunctive therapy ( i.e . laser , atherectomy , cryoplasty , scoring/cutting balloon , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>